Pharmaceutical Sciences

Pharmaceutical sciences encompass the multidisciplinary study of drug discovery, formulation, delivery, pharmacokinetics and pharmacodynamics, with the ultimate aim of developing safe, effective and accessible therapies. This field integrates organic synthesis, medicinal chemistry and high‐throughput screening to identify novel bioactive compounds, while formulation scientists design dosage forms—tablets, capsules, injectables, transdermal patches—that ensure optimal stability, bioavailability and patient compliance. Analytical methods monitor purity, potency and contamination at each stage, and in vitro–in vivo correlations guide early development. Pharmacokinetic and pharmacodynamic modelling characterises a molecule’s absorption, distribution, metabolism and excretion (ADME), informing dose selection and predicting therapeutic and toxic exposures. Cutting‐edge research includes targeted delivery systems—liposomal and nanoparticulate carriers, prodrugs and ligand‐guided platforms—and advanced analytical techniques such as mass spectrometry and nuclear magnetic resonance for structural elucidation. Regulatory science underpins the translation of laboratory discoveries into approved medicines, balancing innovation with rigorous safety and efficacy standards. Emerging areas—artificial intelligence for virtual screening, personalised formulations based on genomic profiling and continuous‐manufacturing technologies—promise to accelerate development timelines and broaden global access to high‐quality medicines.

Research from Nature Portfolio

One study introduced a self‐assembled trio‐pharmacophore DNA‐encoded library that combines three pre‐purified sublibraries to co‐select optimal fragment–linker–fragment combinations. By templating chemical ligation through DNA‐templated synthesis, the resulting library exceeded three hundred million members yet retained drug‐like molecular weights. Screening against proteolytic enzymes and matrix metalloproteases yielded novel inhibitors, demonstrating de novo discovery of high‐affinity ligands through dual‐fragment optimisation.

Another investigation explored the immunometabolic synergy of glycolysis inhibition with locoregional microwave ablation in preclinical breast cancer models. Transient blockade of glycolytic flux by 2‐deoxy‐D‐glucose promoted differentiation of long‐lived central memory CD8⁺ T cells, enhancing durable tumour control and resistance to recurrence. Single‐cell transcriptomics revealed a STAT1‐dependent reprogramming of peripheral T‐cell metabolism, laying the groundwork for clinical trials combining metabolic priming with minimally invasive ablative therapies.

Research from all publishers

A comprehensive review in RSC Advances surveyed recent on‐DNA chemistries for DNA‐encoded libraries, detailing novel cross‐coupling and cycloaddition reactions that proceed under mild, DNA‐compatible conditions. Innovations such as aryl fluorosulfonates have enabled Suzuki, Sonogashira and Buchwald couplings on DNA‐tagged substrates, dramatically expanding accessible chemical space and improving hit quality by enabling diverse scaffolds and heterocycle incorporation without degrading the DNA barcode.

In the Journal of Pharmacokinetics and Pharmacodynamics, researchers developed a three‐compartment population pharmacokinetic model comparing oral docetaxel co‐administered with the P-glycoprotein inhibitor encequidar to standard intravenous regimens. Simulations of multi‐dose oral schedules achieved comparable probability of target attainment for effective exposure, establishing a Go/No-Go decision framework for further clinical evaluation and illustrating how model-informed drug development can optimise alternative administration routes.

Pharmaceutical Sciences publication trend

The graph below shows the total number of articles in pharmaceutical sciences across all publications each year (not limited to Nature Index journals).

Technical terms

DNA‐encoded library: A collection of small molecules each linked to a unique DNA sequence that records its synthetic history, allowing pooled synthesis and high-throughput affinity screening by DNA sequencing.

Split-and-pool synthesis: A combinatorial approach in which reaction mixtures are divided (“split”), each subset modified by a different reagent, then recombined (“pooled”) and re-split for subsequent steps, generating large diverse libraries on DNA tags.

Central memory CD8⁺ T cells (T_CM): A subset of lymphocytes characterised by high expression of CD44 and CD62L that confer long-term immune protection and rapid recall responses after antigen re-exposure.

Probability of target attainment (PTA): The proportion of a population predicted to achieve or exceed a predefined pharmacokinetic exposure index—such as AUC or C_min—at a given dosing regimen, used to guide dosage selection.

Population pharmacokinetic model: A statistical framework—often a nonlinear mixed-effects model—that quantifies typical pharmacokinetic parameters (clearance, volume) and their variability across individuals, identifying influential covariates.

References

1. Introduction: Biopharmaceutics and Pharmacokinetics.
2. Trio-pharmacophore DNA-encoded chemical library for simultaneous selection of fragments and linkers. Nature Communications (2023).
3. Glycolysis inhibition induces anti-tumor central memory CD8+T cell differentiation upon combination with microwave ablation therapy. Nature Communications (2024).
4. DNA-encoded libraries (DELs): a review of on-DNA chemistries and their output. RSC Advances (2021).
5. Oral docetaxel plus encequidar – A pharmacokinetic model and evaluation against IV docetaxel. Journal of Pharmacokinetics and Pharmacodynamics (2024).